PDL BioPharma, Inc.
PDLIV
NASDAQ
Recommendation
Prev Close
--
Volume
--
Avg Vol (90D)
--
Market Cap
--
Dividend & Yield
--
52-Week Range
-- - --
P/E (TTM)
--
EPS (TTM)
| 08/31/2020 | 06/30/2020 | 03/31/2020 | 12/31/2019 | 09/30/2019 | |
|---|---|---|---|---|---|
| Revenue | 32.18M | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 32.18M | -- | -- | -- | -- |
| Cost of Revenue | 5.50M | -- | -- | -- | -- |
| Gross Profit | 5.71M | -- | -- | -- | -- |
| SG&A Expenses | 25.08M | -- | -- | -- | -- |
| Depreciation & Amortization | 637.00K | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 65.29M | -- | -- | -- | -- |
| Operating Income | -33.12M | -- | -- | -- | -- |
| Income Before Tax | -60.25M | -- | -- | -- | -- |
| Income Tax Expenses | -15.55M | -- | -- | -- | -- |
| Earnings from Continuing Operations | -44.70 | -- | -- | -- | -- |
| Earnings from Discontinued Operations | -37.64M | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 645.00K | -- | -- | -- | -- |
| Net Income | -136.58M | -- | -- | -- | -- |
| EBIT | -33.12M | -- | -- | -- | -- |
| EBITDA | -29.45M | -- | -- | -- | -- |
| EPS Basic | -1.60 | -- | -- | -- | -- |
| Normalized Basic EPS | -0.12 | -- | -- | -- | -- |
| EPS Diluted | -1.61 | -- | -- | -- | -- |
| Normalized Diluted EPS | -0.12 | -- | -- | -- | -- |
| Average Basic Shares Outstanding | 357.44M | -- | -- | -- | -- |
| Average Diluted Shares Outstanding | 473.34M | -- | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -0.01% | -- | -- | -- | -- |